The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Recent advances in brain tumor-targeted nano-drug delivery systems
Abstract
INTRODUCTION: Brain tumors represent one of the most challenging and difficult areas in unmet medical needs. Fortunately, the past decade has seen momentous developments in brain tumor research in terms of brain tumor-targeted novel nano-drug delivery systems with significant important superiority over conventional formulations with respect to decreased toxicity and improved pharmacokinetics/pharmacodynamics. AREA COVERED: This review first introduces the characteristics of the two major obstacles in brain-tumor targeted delivery, blood-brain barrier (BBB) and blood-brain tumor barrier (BBTB), and then reviews recent advances in brain tumor-targeted novel nano-drug delivery systems according to their targeting strategies aimed at different stages of brain tumor development and growth. EXPERT OPINION: Based on continuously changing vascular characteristics of brain tumors at different development and growth stages, we propose the concept of 'whole-process targeting' for brain tumor for nano-drug delivery systems, referring to a series of overall targeted drug delivery strategies aimed at key points during the whole development of brain tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
Discher, D. E., & Ahmed, F. (2006) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.8.061505.095838 · Cited by 844
Demeule, M., Currie, J., Bertrand, Y., Ché, C., Nguyen, T., Régina, A., Gabathuler, R., Castaigne, J., & Béliveau, R. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05492.x · Cited by 557 · cited 1×
“Angiopep-2 has been proven to be a dual-functional brain tumor-targeting ligand aimed at the low-density lipoprotein receptor-related protein (LRP), which is overexpressed on both BBB and glioma cells [64,65].”
BackgroundPhage display: Concept, innovations, applications and future
Pande, J., Szewczyk, M. M., & Grover, A. K. (2010) · Biotechnology Advances · doi:10.1016/j.biotechadv.2010.07.004 · Cited by 492
Cole, A. J., David, A. E., Wang, J., Galbán, C. J., Hill, H. L., & Yang, V. C. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.11.040 · Cited by 308
Cited by
Crossing the blood-brain barrier with nanoparticles
Zhou, Y., Peng, Z., Seven, E. S., & Leblanc, R. M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.015 · Cited by 837
“This proposal was based on the fact that glucose and aspartic acid, the starting materials of self-targeting CDs, might be the ligands of these transport proteins [100].”
BackgroundSelf-targeting fluorescent carbon dots for diagnosis of brain cancer cells.
Zheng, M., Ruan, S., Liu, S., Sun, T., Qu, D., Zhao, H., Xie, Z., Gao, H., Jing, X., & Sun, Z. (2015) · ACS Nano · doi:10.1021/acsnano.5b05575 · Cited by 593
Miura, Y., Takenaka, T., Toh, K., Wu, S., Nishihara, H., Kano, M. R., Ino, Y., Nomoto, T., Matsumoto, Y., Koyama, H., et al. (2013) · ACS Nano · doi:10.1021/nn402662d · Cited by 454
Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment
Katsushima, K., Natsume, A., Ohka, F., Shinjo, K., Hatanaka, A., Ichimura, N., Sato, S., Takahashi, S., Kimura, H., Totoki, Y., et al. (2016) · Nature Communications · doi:10.1038/ncomms13616 · Cited by 352
Gao, H., Yang, Z., Zhang, S., Cao, S., Shen, S., Pang, Z., & Jiang, X. (2013) · Scientific Reports · doi:10.1038/srep02534 · Cited by 306
Metadata
- Authors
- Liu, Y., & Lu, W.
- Venue
- Expert Opinion on Drug Delivery
- Publisher
- Informa Healthcare
- Published
- 2012-05-18
- Volume
- 9
- Issue
- 6
- Pages
- 671-686
- ISSN
- 1742-5247 (ISSN-L)
- 1744-7593
- OpenAlex
- W2066336297
- Cited by
- 161
- References
- 5
- FWCI
- 4.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.